Regulus Therapeutics Inc (NASDAQ:RGLS) – Wedbush reduced their FY2017 earnings per share (EPS) estimates for Regulus Therapeutics in a note issued to investors on Monday. Wedbush analyst L. Moussatos now forecasts that the biopharmaceutical company will post earnings per share of ($0.95) for the year, down from their prior forecast of ($0.88). Wedbush has a “Outperform” rating and a $4.00 price objective on the stock. Wedbush also issued estimates for Regulus Therapeutics’ Q2 2018 earnings at ($0.11) EPS, Q3 2018 earnings at ($0.11) EPS, Q4 2018 earnings at ($0.11) EPS, FY2018 earnings at ($0.46) EPS, FY2019 earnings at ($0.48) EPS, FY2020 earnings at ($0.56) EPS and FY2021 earnings at ($0.21) EPS.

Other research analysts have also recently issued research reports about the company. Zacks Investment Research cut Regulus Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, September 19th. Needham & Company LLC reaffirmed a “hold” rating on shares of Regulus Therapeutics in a research report on Tuesday, November 14th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the company’s stock. Regulus Therapeutics presently has an average rating of “Hold” and an average target price of $2.60.

Regulus Therapeutics (NASDAQ RGLS) opened at $0.89 on Wednesday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.77 and a current ratio of 6.77. Regulus Therapeutics has a 1 year low of $0.79 and a 1 year high of $2.75.

Large investors have recently made changes to their positions in the stock. NEA Management Company LLC purchased a new position in Regulus Therapeutics in the third quarter worth $13,737,000. FMR LLC boosted its position in Regulus Therapeutics by 0.5% in the second quarter. FMR LLC now owns 7,977,349 shares of the biopharmaceutical company’s stock worth $7,862,000 after purchasing an additional 37,489 shares during the last quarter. EcoR1 Capital LLC boosted its position in Regulus Therapeutics by 145.6% in the second quarter. EcoR1 Capital LLC now owns 3,709,144 shares of the biopharmaceutical company’s stock worth $3,656,000 after purchasing an additional 2,199,144 shares during the last quarter. South Dakota Investment Council raised its stake in shares of Regulus Therapeutics by 37.1% in the third quarter. South Dakota Investment Council now owns 1,820,027 shares of the biopharmaceutical company’s stock valued at $2,275,000 after buying an additional 492,969 shares during the period. Finally, Candriam Luxembourg S.C.A. bought a new stake in shares of Regulus Therapeutics in the third quarter valued at $750,000. 59.41% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Wedbush Comments on Regulus Therapeutics Inc’s FY2017 Earnings (RGLS)” was posted by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/12/13/wedbush-comments-on-regulus-therapeutics-incs-fy2017-earnings-rgls.html.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Earnings History and Estimates for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.